Recently, we demonstrated that tissue plasminogen activator directly releases fibrinopeptides A and B (FPA and FPB) Invest. 1990. 86:203-212.)
Introduction
The plasminogen activators catalyze the conversion of plasminogen into the enzyme plasmin. Two distinct plasminogen activators have been identified: urokinase-type plasminogen (t-PA). u-PA and t-PA are serine proteinases that have similar structural and catalytic properties. There are important functional differences however, between the two enzymes. Whereas t-PA binds to fibrin, an interaction that dramatically increases its catalytic activity against clot-bound plasminogen (1, 2), u-PA binds to specific receptors found on the plasma membrane of a variety of benign and malignant cell types (3-1 1) . The activity of u-PA is thus localized to the cell surface while that of t-PA is mainly directed against fibrin. Accordingly, the two plasminogen activators may have distinct physiologic roles.
Both u-PA and t-PA are synthesized as single-chain polypeptides that are readily hydrolyzed into two-chain species held together by single disulfide bonds (12) (13) (14) . Although single-chain t-PA is enzymatically active (15) , single-chain u-PA or prourokinase is a zymogen with little or no intrinsic enzymatic activity (16) (17) (18) . Cleavage of the Lys 158-Ile 159 bond of prourokinase generates an active two-chain molecule (54,000 mol wt) referred to as high molecular weight (HMW) urokinase (13) . Subsequent hydrolysis of the Lys 135-Lys 136 bond on the amino-terminal region of HMW urokinase yields another enzymatically active, two-chain form of the enzyme, known as low molecular weight (LMW) urokinase (19) . This species (33,000 mol wt) is the predominant form of urokinase found in commercial preparations of enzyme.
The traditional view is that the plasminogen activators effect fibrinogen proteolysis by activating plasminogen to plasmin. Recently however, we have demonstrated that t-PA can produce limited degradation of fibrinogen under plasminogen-free conditions (20) . Thus, t-PA has a thrombinlike effect on fibrinogen and releases fibrinopeptides A and B (FPA, FPB). The purpose of this study was to determine whether u-PA also has direct catalytic activity against fibrinogen.
Methods
Reagents. Human a-thrombin (sp act, 2,850 U/mg) was generously provided by Dr (20) demonstrated that at a concentration of 5 ,ug/ml it inhibited > 98% of the FPA and FPB released from fibrinogen (0.6 mg/ml) by human a-thrombin (at concentrations in a range of 0.01-0.2 U/ml). Hirudin and PMSF were purchased from Sigma Chemical Co., St. Louis, MO; aprotinin was from FBA Pharmaceuticals, New York. The FPB-containing fragment, Bj1-42, was isolated from a limited plasmin digest of fibrinogen using reverse-phase high-performance liquid chromatography techniques described elsewhere (21) . Synthetic human FPA and FPB were purchased from Bachem, Inc., Torrance, CA.
Urokinase preparations. Prourokinase and LMW urokinase were generously provided by Dr. J. Henkin, Abbott Laboratories, North Chicago, IL. The urokinase preparations were further purified by chromatography on benzamidine-CH Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, NJ). In this way, contaminating two-chain urokinase was removed from the prourokinase preparation, while enzymatically active LMW urokinase absorbed to the benzamidine-CH Sepharose 4B was separated from inactive enzyme after elution with 0.4 M NaCl buffered with 0.1 M ammonium acetate to pH 4.0 (22).
HMW urokinase was generated by incubating prourokinase with immobilized plasmin. Plasminogen was first coupled to cyanogen bromide (CNBr)-activated Sepharose 4B (Pharmacia Fine Chemicals) at a concentration of4 mg/ml. The immobilized plasminogen (2 ml of a 50% suspension) was then converted to plasmin by incubation with 20 gg of LMW urokinase for 30 min at 37°C. After removing the urokinase by centrifugation and repeated washing, immobilized plasmin (1 ml ofa 50% suspension) was mixed with 2.5 mg ofprourokinase and agitated for 40 min at 4°C. After centrifugation, the supernatant was further purified on benzamidine-CH Sepharose 4B as described above. Electrophoresis of 10 ,g of reduced sample on a 10% polyacrylamide gel revealed over 98% conversion of prourokinase to two-chain HMW urokinase.
The activity of the three urokinase preparations was determined by comparing their hydrolysis of L-pyroglutamyl-glycyl-L-arginine-p-nitroanilide (S2444) with that produced by known Radioimmunoassays. FPA was assayed as previously described (24) using antiserum R2 which is specific for this peptide (20, 25, 26) . FPB was quantified as described elsewhere (27) (buffer B) . Peptide samples were eluted from the column using gradients containing various concentrations of buffer B in the mobile phase. 1 -ml fractions were collected, evaporated to dryness, and then assayed for FPA and FPB immunoreactivity. The immunoreactive fractions were pooled, further purified using reverse-phase HPLC, and then subjected to amino acid analysis.
Amino acid analysis. Samples were hydrolyzed in 6N HC1 containing 0.3% phenol in vacuo for 2 h at 1 50'C and then analyzed using standard techniques on an amino acid analyzer (model 6300, Beckman Instruments, Inc.) (32) .
Cleavage of B#1-42 by urokinase. Experiments were performed at 370C in TBS. The FPB-containing peptide B(31-42, diluted in TBS to a final concentration of 1 mg/ml, was incubated with 5 usl of LMW urokinase (1.5 uM) for 2 h at 370C. In a control experiment, the B 1l-42 was incubated with buffer in place-of enzyme. At intervals, aliquots were removed, the reaction was terminated by the addition of PMSF (final concentration, 5 mM), and the samples were then assayed for BP 1-42 and FPB.
Urokinase-mediated proteolysis of BB1-42 also was monitored using reverse-phase HPLC. 20 Mg of BB1-42 suspended in 200 Ml of TBS was incubated with LMW urokinase (2 Mg) or with an equivalent volume of buffer for 2 h at 370C. At the end of the incubation period, proteolysis was stopped by passage of the sample over a Sep-Pak C18 cartridge. Adsorbed peptides were eluted with 3 ml of 50% acetonitrile, evaporated to dryness, dissolved in 0.1% trifluoroacetic acid, and then subjected to HPLC analysis using native B(31 -42, BB15-42, and FPB as internal standards. 1 -ml fractions were collected and assayed for Bj1-42 and FPB.
Estimation ofthe kinetic parametersfor urokinase-mediated cleavage of the B1(14 (Arg)-B3 15 (Gly) bond of fibrinogen. Experiments were performed in TBS at 37°C. l-ml aliquots of fibrinogen (at concentrations in a range of 0.74-14.7 MM) were incubated with 500 IU/ml (130 nM) LMW urokinase for 120 min. At intervals, 100-Ml aliquots were removed, the reaction was terminated by the addition of PMSF (5 mM, final concentration), and the fibrinogen was precipitated by the addition of 300 Ml of chilled ethanol followed by centrifugation at 15,000 g for 5 min. The ethanol supernatants were then evaporated to dryness, reconstituted to original volume with distilled ethanol, and assayed for FPB.
At each fibrinogen concentration, the velocity of FPB release was calculated by measuring the appearance of FPB immunoreactivity during the initial 40 min ofthe reaction. Release was linear during this interval, and < 10% of the substrate was consumed.
Thrombin clotting times of urokinase-treatedfibrinogen. Fibrinogen, suspended in TBS at a concentration of 1.2 mg/ml, was incubated with LMW urokinase (at concentrations in a range of 0.1-0.3 WM) for 2 h at 37°C. In control experiments, the fibrinogen was incubated with buffer in place of enzyme. At intervals, 250-Ml1 aliquots were taken and the urokinase was removed by incubation with benzamidine-Sepharose (100 Ml ofa 50% suspension) for 20 min at room temperature with constant agitation. After centrifugation at 15,000 g for 5 min, the supernatants were removed and the fibrinogen concentration was determined by measuring both the protein concentration according to the method of Lowry et al. (33) , and the absorbance at 280 nm using an extinction coefficient of 1.55. After adjusting the concentration of fibrinogen to 0.5 mg/ml, thrombin clotting times were determined using bovine thrombin (Parke-Davis and Co., Detroit, MI) at 10 U/ml in TBS.
Thrombin-mediatedfibrinopeptide release from urokinase-treated fibrinogen. Experiments were performed at 37°C in TBS. 1-ml samples of fibrinogen (1.2 mg/ml) were incubated with LMW urokinase (at concentrations in a range of0.1-0.3 MM) for 2 h. Control samples were incubated with buffer in place of enzyme. The urokinase was then removed by incubation with benzamidine-Sepharose (400 M1 of a 50% suspension) for 20 min at room temperature with constant agitation.
After centrifugation at 5,000 g for 5 min, the supernatants were extensively dialyzed against TBS to remove released peptide fragments, and the fibrinogen concentrations adjusted to 0.46 mg/ml.
Control and urokinase-treated fibrinogen preparations were incubated with 0.02 U/ml human a-thrombin for 2 h at 37°C. At intervals, 100-Mi aliquots were removed, the reaction was terminated by the addition of0.1 U ofhirudin, and unreacted fibrinogen was precipitated with 300 MI ofchilled ethanol followed by centrifugation at 15,000 gfor 5 min. The ethanol supernatants were then evaporated to dryness, reconstituted to original volume with distilled water, and assayed for FPA and FPB.
Urokinase-mediated generation of FPB and B1(1-42 in plasma.
Using a 21-gauge butterfly needle, blood was collected from an antecubital vein of healthy volunteers into 10-ml vacutainer tubes prefilled with 143 U of sodium heparin (Becton, Dickinson & Co., Toronto, Ont.). The red cells were sedimented by centrifugation at 1,700 g for 15 min at 4VC and the plasma was harvested. LMW urokinase (at concentrations in a range of 25-250 nM) was incubated with 250-M1 aliquots of heparinized plasma for 60 min at 370C in the absence or presence of aprotinin (500 KIU/ml) or a2-antiplasmin (1 MM, final concentration). The reaction was then terminated by the addition of PMSF (5 mM, final concentration), and the fibrinogen was precipitated by the addition of 750 Ml of chilled ethanol followed by centrifugation at 15,000 g for 5 min. The (Fig. 1) . This is in direct contrast to thrombin (27, 34) or t-PA (20) which releases both fibrinopeptides. By plotting the amount of FPB released from fibrinogen after 60 min of incubation as a function of the urokinase concentration, a doseresponse curve was constructed (Fig. 2) . At concentrations of 1 MM or higher, urokinase produces quantitative release of FPB (2 mol/mol fibrinogen), and no FPA cleavage.
Comparison ofthe FPB-releasing activity ofprourokinase, HMW urokinase, and LMW urokinase. The FPB-releasing activity of prourokinase and HMW urokinase was compared with that of LMW urokinase (Fig. 3) . For equivalent amidoly- tic activity, HMW urokinase releases approximately twofold more FPB than does the LMW form. In contrast, prourokinase does not release FPB. When the prourokinase is converted to urokinase however, there is FPB release similar in amount to that produced by two-chain urokinase (data not shown). These findings are consistent with the concept that prourokinase is a zymogen and lacks intrinsic enzymatic activity (16) (17) (18) . HPLC separation of the products of urokinase-mediated fibrinogenolysis. To confirm that the increase in FPB immunoreactivity after urokinase incubation with fibrinogen represents release ofthe free peptide, the products of urokinase-mediated fibrinogenolysis were separated by reverse-phase HPLC using synthetic FPA and FPB as internal standards. l-ml fractions were collected and assayed for FPA and FPB immunoreactivity (Fig. 4) . A single FPB immunoreactive peak that coeluted with synthetic FPB was identified. In contrast, no FPA immunoreactivity was detected. The FPB immunoreactive fractions were then pooled and subjected to amino acid analysis. The fragment released by urokinase was further characterized as FPB by its amino acid composition (Table I ).
Effect of inhibitors and an antibody against urokinase on urokinase-mediated FPB release. To exclude the possibility that urokinase-mediated FPB release is the result ofa contaminating proteinase, the effect of a variety of inhibitors was investigated (Table II) . FPB release is unaffected by hirudin or by a monospecific antibody against thrombin, indicating that thrombin is not responsible for this activity. In addition, a2-antiplasmin and aprotinin have no effect, thereby excluding plasmin as the mediator of urokinase-induced FPB release. In contrast, peptide release is almost completely abolished by PMSF, and by a monospecific antibody against urokinase. These studies thus indicate that urokinase is the serine proteinase responsible for FPB release.
Urokinase-mediated FPB (Fig. 5) . Separation of the products of urokinase-mediated proteolysis of BA1-42 reveals a decrease in the BB1-42 peak associated with the appearance oftwo new peaks (Fig. 5 B) Fibrinogen proteolysis is not the result of contaminating plasmin since degradation is unaffected by aprotinin, and is unaccompanied by B 1-42 release. Further, this activity is abolished by a monospecific antibody against urokinase. Finally, no cleavage of the Aa-or Bj3-chains is evident by SDS-PAGE analysis when the fibrinogen is incubated with streptokinase or recombinant t-PA in place of urokinase (data not shown), indicating that proteolysis at these sites is a property unique to urokinase.
Thrombin clotting times of urokinase-treated fibrinogen. Incubation of fibrinogen with LMW urokinase produces progressive prolongation ofthe thrombin clotting times so that the fibrinogen is unclottable after 90 min (Fig. 8) . To determine whether this reflects impaired polymerization, control fibrinogen was mixed with either unclottable urokinase-treated fibrinogen or saline, and the thrombin clotting times of these mixtures were then compared (Table III) . Dilution with urokinase-treated fibrinogen has the same effect on the thrombin clotting time as the addition ofan equivalent volume ofsaline, indicating that the urokinase-treated material does not affect the clottability of normal fibrinogen. jig of BP1-42 was injected onto the column using a flow rate of 1 ml/ min. 1-ml fractions were collected, evaporated to dryness, and then assayed for B 1-42 and FPB immunoreactivity. (B) BB1-42 (20 jig) was incubated with urokinase (2 jig) for 2 h at 370C. The reaction was terminated by passage of the sample over a C 18 cartridge. Adsorbed peptides were eluted with 3 ml of 50% acetonitrile, evaporated to dryness, and dissolved in 0.1% trifluoroacetic acid. -25% of the starting material was then injected onto the column using the same flow rate. I-ml fractions were collected, evaporated to dryness, and then assayed for BPl-42 and FPB immunoreactivity. Urokinase *--+ Figure 7 . FPA release, the time course of thrombin-mediated fibrinopeptide release from urokinase-treated fibrinogen was compared with that from control fibrinogen (Fig. 9 ). There is no FPB release from the urokinase-treated material, confirming the prior cleavage of this peptide by urokinase. Urokinase-mediated generation of FPB and B#1-42 in plasma. To determine whether urokinase-mediated release of FPB occurs in the presence of physiologic concentrations of antiproteinases, increasing concentrations of urokinase were incubated with heparinized plasma (Fig. 10) . The plasma levels of BfB1-42 were monitored as an index of urokinase activation of plasminogen and subsequent attack on fibrinogen by unopposed plasmin. At the same time, the direct cata- Urokpms f1pM Figure 10 . Urokinase-mediated generation of BjB1-42 and desarginine FPB in heparinized plasma. LMW urokinase (26 nM to 0.7 AM) was incubated with heparinized plasma for 60 min at 370C. The reaction was terminated and unreacted fibrinogen was precipitated with ethanol, and the ethanol supernatants were then assayed for lytic activity of urokinase against fibrinogen was assessed by measuring the levels of desarginine FPB, the stable carboxypeptidase-derived metabolite of FPB (28, 29) .
In plasma, urokinase produces concentration-dependent release of both BP1-42 and desarginine FPB (Fig. 10) . At each concentration of enzyme, the levels of Bj 1-42 are two-to fourfold higher than those ofdesarginine FPB. With urokinase concentrations of0. 16 The generation of desarginine FPB by urokinase could be caused either by direct cleavage of FPB from fibrinogen or FPB could be released from the plasmin-derived BB1-42 fragment as illustrated in Fig. 5 . To determine the relative contribution of each of these pathways, B 1-42 release was blocked by the addition of a2-antiplasmin (Fig. 10) or aprotinin (data not shown) and desarginine FPB levels were measured. The residual desarginine FPB reflects the direct action of urokinase on fibrinogen, since these inhibitors have minimal effects on urokinase-mediated FPB release from fibrinogen (Table II) . In the presence of a2-antiplasmin or aprotinin, there remains concentration-dependent release of desarginine FPB, albeit to a much lesser extent, despite almost complete inhibition of BPI1-42 release. These data thus demonstrate that urokinasemediated generation of desarginine FPB in plasma is the result of hydrolysis of both fibrinogen, and the plasmin-derived BB1-42 fragment.
Discussion
This study demonstrates that urokinase, like t-PA (20) , also has direct catalytic activity against fibrinogen. In contrast to t-PA, however, urokinase only releases FPB, and also cleaves the Aa-chains of fibrinogen. On a mole for mole basis, urokinase releases considerably more FPB than does t-PA. Thus, quantitative FPB release (2 mol FPB/mol fibrinogen) is effected by urokinase concentrations of 1 ,uM or more (Fig. 2) , whereas our previous studies demonstrated that similar concentrations of t-PA release < 10% of the available FPB (20) .
Confirmation that the increase in FPB immunoreactivity that occurs when urokinase is incubated with fibrinogen reflects release of the free peptide ( Figs. 1 and 2 ) comes from the HPLC demonstration that the FPB immunoreactive peak in the digestion mixture coelutes with native or synthetic FPB (Fig. 3) . This material was further characterized as FPB by its amino acid composition ( Table I) .
The pattern of urokinase-mediated fibrinopeptide release is different from that produced by thrombin, since thrombin releases both FPA and FPB from fibrinogen (27, 34) . Furthermore, release ofFPB by urokinase occurs in the presence ofthe thrombin inhibitors, heparin (Fig. 10 ) and hirudin (Table II) , and is unaffected by a monospecific antibody against thrombin ( Table-II) . Contaminating plasmin is not responsible for FPB release by urokinase because a2-antiplasmin and aprotinin have no effect on this activity (Table II) . In addition, plasmin releases B# 1-42 from fibrinogen (30, 36) , rather than FPB, and no BlB142 was detected in the digestion mixture.
That FPB release is due to the direct catalytic activity of urokinase is illustrated by the virtually complete inhibition of this reaction with a monospecific antibody against urokinase (Table II) . Further, urokinase releases FPB from the FPB-containing substrate B#31-42 (Fig. 5) , thereby confirming its specificity for the B( 14-15 bond. Finally, FPB release is effected by both HMW and LMW urokinase (Fig. 3) , indicating that FPB release is a property ofboth forms oftwo-chain urokinase. For equivalent amidolytic activity, however, HMW urokinase has approximately twofold greater FPB releasing activity than the LMW species. In contrast, prourokinase does not release FPB from fibrinogen, consistent with previous reports that prourokinase is a zymogen that has little or no intrinsic enzymatic activity until activated to urokinase (16) (17) (18) .
To determine whether urokinase cleaves other sites on the fibrinogen molecule, the time-course of urokinase-mediated fibrinogenolysis also was monitored by SDS-PAGE (Fig. 7) . Urokinase produces progressive proteolysis of the Aa-and Bfl-chains which becomes apparent at 60 min of incubation, and continues over the subsequent 4 h. In contrast, the release of FPB is completed by 40 min, indicating that the B, 14 (Arg)-B# 15 (Gly) bond is the preferred site of urokinase cleavage.
Urokinase cleavage of fibrinogen results in progressive prolongation of the thrombin clotting time (Fig. 8) so that the fibrinogen becomes unclottable by 90 min. This is not the result of impaired FPA release since thrombin induces quantitative (2 mol/mol fibrinogen) release of FPA from urokinasetreated fibrinogen (Fig. 9) . The decrease in clottability appears to coincide with the subsequent proteolysis of the Aa-and Bfl-chains. The most likely explanation for the prolonged clotting times, therefore, is that progressive urokinase-mediated proteolysis either cleaves or alters the conformation of a critical polymerization domain on the fibrinogen molecule.
The finding that urokinase has direct catalytic activity against fibrinogen is consistent with recent evidence that this enzyme has specificity for substrates other than plasminogen. Quigley et al. (37), demonstrated that urokinase degrades fibronectin under plasminogen-free conditions and releases several high molecular weight cleavage products. More recently, urokinase also has been shown to cleave and activate diphtheria toxin (38) .
Comparison of the kinetic parameters for urokinase cleavage of the B#314 (Arg)-B 1 5 (Gly) bond of fibrinogen with those reported for urokinase activation of Glu-plasminogen indicate that Glu-plasminogen is the preferred substrate in buffer systems. Despite these observations however, the incubation of urokinase with heparinized plasma results in the generation of both the plasmin-derived B31-42 fragment and desarginine FPB (Fig. 10) , and the levels of B#1-42 are only two to fourfold higher than those of desarginine FPB. There are two explanations for the higher than expected levels of desarginine FPB in plasma. First, a2-antiplasmin inhibits plasmin-mediated B31-42 release without affecting the direct action of urokinase on fibrinogen (Table II) . Secondly, the FPB that is generated in plasma is not only derived from direct urokinase cleavage of fibrinogen but also is a product of secondary urokinase-mediated attack on the plasmin-derived B 1-42 fragment. The present study indicates that urokinase has direct catalytic activity against fibrinogen that results in release of FPB, and cleavage of the carboxy terminals of the Aa-chains. Both of these effects may be physiologically relevant. Recent evidence indicates that a wide variety of mammalian cells synthesize u-PA (39) (40) (41) . Secreted or circulating u-PA binds to receptors found on inflammatory cells (42, 43) . With the accumulation of these cells in thrombi or at extravascular sites of inflammation or tissue repair, the local concentrations ofu-PA may reach those used in this study. Surface-bound enzyme is protected from circulating inhibitors (41, 44) . In addition, the close apposition of u-PA bearing cells to fibrinogen may prevent access of antiproteinases to enzymes released at the cellsubstrate interface (45) (46) (47) (48) (49) , thereby producing a protected environment in which urokinase can degrade fibrinogen. Through localized release of FPB, a potent chemoattractant for neutrophils (50, 5 1) and fibroblasts (5 1), urokinase has the potential to recruit more inflammatory and/or mesenchymal cells which can then amplify the inflammatory process. In addition, proteolysis ofthe Aa-chains offibrinogen renders the molecule less clottable by thrombin and so has the potential to modulate thrombogenesis at sites of vessel injury.
